CLSD
Clearside Biomedical, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.41
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.3M | 1.7M | 8.2M | 1.3M | 29.6M |
| Cost of Revenue | 481.0K | 149.0K | 355.0K | 204.0K | — |
| Gross Profit | 2.8M | 1.5M | 7.9M | 1.1M | 29.6M |
| Operating Expenses | |||||
| R&D Expense | 13.2M | 18.6M | 20.8M | 19.6M | 18.5M |
| SG&A Expense | 12.7M | 11.8M | 11.9M | 11.8M | 11.7M |
| General & Admin Expense | 12.7M | 11.8M | 11.9M | 11.8M | 11.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (84.0K) | — | — | — | — |
| Total Operating Expenses | 25.8M | 30.4M | 32.7M | 31.4M | 30.2M |
| Cost and Expenses | 26.3M | 30.5M | 33.1M | 31.6M | 30.2M |
| Operating Income (EBIT) | (23.0M) | (28.9M) | (24.8M) | (30.3M) | (627.0K) |
| Non-Operating | |||||
| Interest Income | 701.0K | 1.5M | 1.7M | 669.0K | — |
| Interest Expense | 10.6M | 9.8M | 9.4M | 3.3M | — |
| Net Interest Income | (9.9M) | (8.3M) | (7.6M) | (2.7M) | — |
| Other Non-Op Income/Expense | (2.3M) | (5.5M) | (7.6M) | (2.7M) | 1.0M |
| Non-Operating Income (excl Interest) | (8.3M) | (4.3M) | (1.7M) | (669.0K) | (1.0M) |
| EBT (Pre-Tax Income) | (25.3M) | (34.4M) | (32.5M) | (32.9M) | 376.0K |
| Income Tax Expense | 715.0K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (26.0M) | (34.4M) | (32.5M) | (32.9M) | 376.0K |
| Earnings from Cont. Ops | (26.0M) | (34.4M) | (32.5M) | (32.9M) | 376.0K |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (26.0M) | (34.4M) | (32.5M) | (32.9M) | 376.0K |
| Per Share | |||||
| Basic EPS | ($5.10) | ($7.05) | ($7.95) | ($8.25) | $0.10 |
| Diluted EPS | ($5.10) | ($7.05) | ($7.95) | ($8.25) | $0.09 |
| Revenue Per Share | $0.64 | $0.34 | $2.00 | $0.33 | $7.58 |
| Shares | |||||
| Basic Shares Outstanding | 5.2M | 4.9M | 4.1M | 4.0M | 3.9M |
| Diluted Shares Outstanding | 5.2M | 4.9M | 4.1M | 4.0M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | (14.4M) | (24.3M) | (23.1M) | (29.5M) | 554.0K |
| D&A | 332.0K | 226.0K | 67.0K | 145.0K | 178.0K |
| EBIT | (14.7M) | (24.6M) | (23.1M) | (29.6M) | 376.0K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025